ROUTINE DETERMINATION OF [F-18] L-6-FLUORODOPA AND ITS METABOLITES IN BLOOD-PLASMA IS ESSENTIAL FOR ACCURATE POSITRON EMISSION TOMOGRAPHY STUDIES

被引:23
作者
CHAN, GLY
HEWITT, KA
PATE, BD
SCHOFIELD, P
ADAM, MJ
RUTH, TJ
机构
[1] UNIV BRITISH COLUMBIA,TRIUMF,VANCOUVER V6T 1W5,BC,CANADA
[2] UNIV BRITISH COLUMBIA,DEPT MED,DIV NEUROL,VANCOUVER V6T 1W5,BC,CANADA
基金
英国医学研究理事会;
关键词
D O I
10.1016/0024-3205(92)90339-Q
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
A batch-contact alumina-extraction method has been used to separate [F-18]-L-6-fluorodopa (FD) from its principal metabolite, 3-O-methyl-[F-18]-6-fluorodopa (3-OMe-FD), in arterial blood plasma samples collected from subjects pretreated with carbidopa during positron emission tomography (PET) scans. The time course of the metabolite-corrected blood plasma activity is then used as an input function for kinetic analysis of striatal FD uptake. Results obtained from using the batch-contact alumina-extraction method were compared with those from high performance liquid chromatography, and also with those from a chromatographic alumina cartridge technique developed in this laboratory. In 60 human subjects including normal healthy volunteers and patients diagnosed as having a movement disorder, arterial blood plasma samples were collected after FD injection during a two-hour PET scan and analyzed by the batch-contact alumina-extraction method. The activity ratio (metabolites/FD) increased linearly with time for all subjects. However, there was a wide variation in the slope of the plot of the activity ratio (metabolites/FD) versus time among the subjects. No significant linear or curved relationship was observed between the slope and the age of the subject. Separation of FD from its metabolites is therefore necessary for each PET-FD study conducted.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 12 条
[1]  
ADAM MJ, 1988, APPL RADIAT ISOTOPES, V39, P1203
[2]  
ADAM MJ, 1986, J NUCL MED, V27, P1462
[3]   DETERMINATION OF PLASMA [F-18] 6-FLUORODOPA DURING POSITRON EMISSION TOMOGRAPHY - ELIMINATION AND METABOLISM IN CARBIDOPA TREATED SUBJECTS [J].
BOYES, BE ;
CUMMING, P ;
MARTIN, WRW ;
MCGEER, EG .
LIFE SCIENCES, 1986, 39 (23) :2243-2252
[4]  
CUMMING P, 1987, J NEUROCHEM, V48, P601
[5]  
FIRNAU G, 1988, J NUCL MED, V29, P363
[6]  
HOLDEN J E, 1991, Journal of Nuclear Medicine, V32, P1007
[7]   NIGROSTRIATAL FUNCTION IN HUMANS STUDIED WITH POSITRON EMISSION TOMOGRAPHY [J].
MARTIN, WRW ;
PALMER, MR ;
PATLAK, CS ;
CALNE, DB .
ANNALS OF NEUROLOGY, 1989, 26 (04) :535-542
[8]  
MARTIN WRW, 1985, J CEREB BLOOD FLO S1, V5, pS593
[9]   COMPARATIVE INVIVO METABOLISM OF 6-[F-18]FLUORO-L-DOPA AND [H-3] L-DOPA IN RATS [J].
MELEGA, WP ;
LUXEN, A ;
PERLMUTTER, MM ;
NISSENSON, CHK ;
PHELPS, ME ;
BARRIO, JR .
BIOCHEMICAL PHARMACOLOGY, 1990, 39 (12) :1853-1860
[10]   THE EFFECTS OF CARBIDOPA ON THE METABOLISM OF 6-[F-18]FLUORO-L-DOPA IN RATS, MONKEYS AND HUMANS [J].
MELEGA, WP ;
HOFFMAN, JM ;
LUXEN, A ;
NISSENSON, CHK ;
PHELPS, ME ;
BARRIO, JR .
LIFE SCIENCES, 1990, 47 (02) :149-157